| Page Out E E LA JUN 9 A 2005 IN THE UNITED STATES PATENT A | PATENT Case No. 21176YP |
|--|-------------------------|
| Serial No. 10/576,796 Filed: April 21, 2006 For: SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | Art Unit: |
| Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 | : |

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement, shall not be construed to mean that a search has been made
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

DEL ATER ARRIVATION

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited

by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120

are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

| | RELATED APPLICATION | | | | |
|---|---|--|--|--|--|
| U. S. SERIAL NUMBER | FILING DATE | MERCK CASE | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| If this is inconvenient, additional copies will be submitted upon r | equest. | | | | |
| 6. In accordance with 37 C.F.R. 1.97, (check one) | | | | | |
| the attached information is filed within three months of the file | ing date of the captioned case. | | | | |
| the attached information is filed more than three months after Office Action on the merits. | er the filing date but prior to the | mailing of a first | | | |
| the attached information is filed before the mailing of a first 0 examination under §1.114. | Office action after the filing of a | request for continued | | | |
| the attached information is being filed more than three mont Office Action on the merits, but before the mailing date of a otherwise closes prosecution in the application. The enclos Account No. 13-2755 for the fee required under 37 C.F.R. 1 | Final Action, Notice of Allowand ed authorization is therefore giv | e, or an action that | | | |
| each item of information contained in this Information Disclo from a foreign patent office in a counterpart foreign applicati Statement. | sure Statement was first cited in not more than three months | n any communication prior to the filing of thi | | | |
| each item of information contained in the information disclos from a foreign patent office in a counterpart application and designated in §1.56(c) more than thirty days prior to the filin | this communication was not red | ceived by any individua | | | |
| no item of information contained in this Information Disclosu foreign patent office in a counterpart foreign application, and after making reasonable inquiry, was known to any individual months prior to the filing of this Statement. | , to the knowledge of the perso | n signing the certificat | | | |
| | | | | | |

By: CATHERINE D. FITCH
Attorney For Applicant(s)
Reg. No. 36.502
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732)594-4283
Date: Quant 22, 2004

Respectfully submitted,

| _ | | _ | | | Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE | | |
|-----------------------------------|-------------------------------|-----|-----------|------------------------|---|--|--|
| | Substitute for form 1449A/PTO | | | COMPLETE IF KNOWN | | | |
| | INFORMATION | | | Application Number | 10/576,796 | | |
| / | STATEMENT BY | A D | DI ICANT | Filing Date | April 21, 2006 | | |
| JUN 2 6 2006 38 | | | | First Named Inventor | J.S. Debenham et al. | | |
| | | | | Group Art Unit | | | |
| (use as mgs) sheets as necessary) | | | ecessary) | Examiner Name | | | |
| Shee | t TRAD | of | 3 | Attorney Docket Number | 21176YP | | |

| | | U.S. Patent Document | | | Date of Publication of |
|---------------------|-------------|----------------------|----------------------------|--|------------------------------|
| xaminer nitials* | Cite No. | Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Cited Document MM-DD-YYYY |
| RD | | 6344474 | | Maruani et al. | 02/05/2002 |
| RD | | 2005/0143381 | | Yu et al. | 06/30/2005 |
| RD | | 2004/0214838 | | Carpino et al. | 10/28/2004 |
| RD | | 2004/0214855 | | Carpino et al. | 10/28/2004 |
| RD | | 2004/0214856 | | Carpino et al. | 10/28/2004 |
| RD | | 2004/0248881 | | Carpino et al. | 12/09/2004 |
| RD | | 2005/272763 | | Toupence et al. | 12/08/2005 |
| RD | | 2005/085493 | | Brain et al. | 04/21/2005 |
| RD | | 2005/0203112 | | Castonguay et al. | 09/15/2005 |
| RD | | 2006/0094714 | | Bullock et al. | 05/04/2006 |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| RD RD RD | Foreign Patent Docume Office Number WO 2004/087704 WO 99/02499 | Kind Code (if known) | Name of Patentee or Applicant of Cited Document AstraZeneca AB | Date of Publication of Cited Document MM-DD-YYYY |
|----------------|--|----------------------------|--|--|
| RD RD | WO 99/02499 | | AstraZeneca AB | 10/14/2004 |
| RD | | | | |
| | | 1 1 | Japan Tobacco Inc. | 01/21/1999 |
| | WO 2005/021547 | | Pharmaxis Pty Ltd. | 03/10/2005 |
| RD | WO 2005/061504 | 1 | Pfizer Products Inc. | 07/07/2005 |
| RD | WO 2005/061507 | | Pfizer Products Inc. | 07/07/2005 |
| RD | WO 2005/061505 | 1 | Pfizer Products Inc. | 07/07/2005 |
| RD | WO 2005/049615 | | Pfizer Products Inc. | 06/02/2005 |
| RD | WO 2005/035532 | 1 | Pfizer Products Inc. | 04/21/2005 |
| RD | WO 2005/103052 | 1 | Pfizer Products Inc. | 01/03/2005 |
| RD | WO 2004/060882 | | AstraZeneca AB | 07/22/2004 |

| | | | | | Facilitate Fragelica Control |
|-------|------------------------------|----------------------|----------------------|------------------------|------------------------------|
| Su | sbstitute for form 1449A/PTO | | | | COMPLETE IF KNOWN |
| I | NFORMATION | DIS | CLOSURE | Application Number | 10/576,796 |
| | STATEMENT BY APPLICANT | | DI ICANT | Filing Date | April 21, 2006 |
| 3 | STATEMENT BY APPLICANT | First Named Inventor | J.S. Debenham et al. | | |
| | | | | Group Art Unit | |
| | (use as many sheets | as r | necessary) | Examiner Name | |
| Sheet | 2 | of | 3 | Attorney Docket Number | 21176YP |

| | | | U.S. PATE | NT DOCUMENTS | |
|-----------------------|-------------|--------------------------------|----------------------------|---|--|
| Examiner Initials* | Cite No. | U.S. Patent Document Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | | 17 | | |
| | - | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | - | | | | |
| | | | - | | |
| | | | - | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | 1 | | |
| | | | | | |
| | _ | | | | |
| | | | | | |
| | | | | | |
| | 1 | | | | |
| | | | | | |
| | | | | | |
| | - | | + | | |

| | | | FORE | IGN PATEN | T DOCUMENTS | |
|-----------------------|----------------------------------|--------|--------------|----------------------------|---|---------------------------|
| | ner Cite Foreign Patent Document | | | | Date of Publication of | |
| Examiner Initials* | No. | Office | Number | Kind Code (if known) | Name of Patentee or Applicar of Cited Document | Cited Document MM-DD-YYYY |
| RD | | woo | 3/086394 | | Merck & Co., Inc. | 10/23/2003 |
| | - | | | | | |
| | - | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Examin- Signatur | er re | | /RITA DESAI, | / | Date Considered | 6/03/09 |

*Examiner. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Su | Substitute for form 1449B/PTO | | COMPLETE IF KNOWN | | | |
|-------|-----------------------------------|------|-------------------|------------------------|----------------------|--|
| I | NFORMATION | DIS | CLOSURE | Application Number | 10/576,796 | |
| | TATEMENT DV | A TO | DI ICANT | Filing Date | April 21, 2006 | |
| 3 | STATEMENT BY APPLICANT | | | First Named Inventor | J.S. Debenham et al. | |
| | 6 | | | Group Art Unit | - | |
| | (use as many sheets as necessary) | | | Examiner Name | | |
| Sheet | 3 | of | 3 | Attorney Docket Number | 21176YP | |

| | | NON PATENT LITERATURE DOCUMENTS |
|-----------------------|-------------|--|
| Examiner Initials* | Cite No. | Include name of the author, title, date, page(s), volume-issue number(s) and place of publication. |
| RD | AA | Ferrarini et al., Bioorg. & Medicinal Chem., Vol. 12 (2004), pp. 1921-1933, "Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors" |
| RD | ΑВ | Lange et al., Current Opin. in Drug Discovery & Develop., Vol. 7 (2004), pp. 498-506, "Recent advances in CB1 cannabinoid receptor antagonists" |
| RD | AC | Pertwee, Exp. Opin. Invest. Drugs, Vol., 9 (2000), pp. 1553-1571, "Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development" |
| RD | AD | Pertwee, Addiction Biology, Vol. 5 (2000), pp. 37-46, "Neuropharmacology and therapeutic potential of cannabinoids" |
| RD | AE | Evens et al., American Chem. Society, Vol. 12 (1979), "Poly(1,8-naphthyridines) and 1,9,10-anthyridines: Model systems for "Black Orlon" |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | 7.1 - 7.1 |
| | | |
| | | |
| | | |
| | | |

| | | | | $\overline{}$ |
|-----------|--------------|------------|---------|---------------|
| Examiner | /RITA DESAI/ | Date | 6/03/09 | 1 |
| Signature | /RITA DESAI/ | Considered | 6/03/09 | |